Ting Cai1, Jinxin Qiu1, Yan Ji1, Wenjing Li2, Zhaoyun Ding1, Caixia Suo1, Jiali Chang1, Jingjing Wang1, Rui He2, Youcun Qian1, Xiaohuan Guo3, Liang Zhou4, Huiming Sheng5, Lei Shen6, Ju Qiu7. 1. CAS Key Laboratory of Tissue Microenvironment and Tumor, Shanghai Institute of Nutrition and Health, Shanghai Institutes for Biological Sciences, University of Chinese Academy of Sciences, Chinese Academy of Sciences, Shanghai, China. 2. Department of Immunology, School of Basic Medical Sciences, Fudan University, Shanghai, China. 3. Institute for Immunology, Tsinghua University, Beijing, China; Department of Basic Medical Sciences, School of Medicine, Tsinghua University, Beijing, China. 4. Department of Infectious Diseases and Immunology, College of Veterinary Medicine, University of Florida, Gainesville, Fla. 5. Tongren Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. Electronic address: polosheng@alumni.sjtu.edu.cn. 6. Shanghai Institute of Immunology, Shanghai Key Laboratory for Tumor Microenvironment and Inflammation, Shanghai Jiao Tong University School of Medicine, Shanghai, China. Electronic address: lshen@shsmu.edu.cn. 7. CAS Key Laboratory of Tissue Microenvironment and Tumor, Shanghai Institute of Nutrition and Health, Shanghai Institutes for Biological Sciences, University of Chinese Academy of Sciences, Chinese Academy of Sciences, Shanghai, China. Electronic address: qiuju@sibs.ac.cn.
Abstract
BACKGROUND: IL-17 plays a pathogenic role in asthma. ST2- inflammatory group 2 innate lymphoid cells (ILC2s) driven by IL-25 can produce IL-17, whereas ST2+ natural ILC2s produce little IL-17. OBJECTIVE: We characterized ST2+IL-17+ ILC2s during lung inflammation and determined the pathogenesis and molecular regulation of ST2+IL-17+ ILC2s. METHODS: Lung inflammation was induced by papain or IL-33. IL-17 production by lung ILC2s from wild-type, Rag1-/-, Rorcgfp/gfp, and aryl hydrocarbon receptor (Ahr)-/- mice was examined by using flow cytometry. Bone marrow transfer experiments were performed to evaluate hematopoietic myeloid differentiation primary response gene-88 (MyD88) signaling in regulating IL-17 production by ILC2s. mRNA expression of IL-17 was analyzed in purified naive ILC2s treated with IL-33, leukotrienes, and inhibitors for nuclear factor of activated T cells, p38, c-Jun N-terminal kinase, or nuclear factor κ light-chain enhancer of activated B cells. The pathogenesis of IL-17+ ILC2s was determined by transferring wild-type or Il17-/- ILC2s to Rag2-/-Il2rg-/- mice, which further induced lung inflammation. Finally, expression of 106 ILC2 signature genes was compared between ST2+IL-17+ ILC2s and ST2+IL-17- ILC2s. RESULTS: Papain or IL-33 treatment boosted IL-17 production from ST2+ ILC2s (referred to by us as ILC217s) but not ST2- ILC2s. Ahr, but not retinoic acid receptor-related orphan receptor γt, facilitated the production of IL-17 by ILC217s. The hematopoietic compartment of MyD88 signaling is essential for ILC217 induction. IL-33 works in synergy with leukotrienes, which signal through nuclear factor of activated T-cell activation to promote IL-17 in ILC217s. Il17-/- ILC2s were less pathogenic in lung inflammation. ILC217s concomitantly expressed IL-5 and IL-13 but expressed little GM-CSF. CONCLUSION: During lung inflammation, IL-33 and leukotrienes synergistically induce ILC217s. ILC217s are a highly pathogenic and unexpected source for IL-17 in lung inflammation.
BACKGROUND:IL-17 plays a pathogenic role in asthma. ST2- inflammatory group 2 innate lymphoid cells (ILC2s) driven by IL-25 can produce IL-17, whereas ST2+ natural ILC2s produce little IL-17. OBJECTIVE: We characterized ST2+IL-17+ ILC2s during lung inflammation and determined the pathogenesis and molecular regulation of ST2+IL-17+ ILC2s. METHODS:Lung inflammation was induced by papain or IL-33. IL-17 production by lung ILC2s from wild-type, Rag1-/-, Rorcgfp/gfp, and aryl hydrocarbon receptor (Ahr)-/- mice was examined by using flow cytometry. Bone marrow transfer experiments were performed to evaluate hematopoietic myeloid differentiation primary response gene-88 (MyD88) signaling in regulating IL-17 production by ILC2s. mRNA expression of IL-17 was analyzed in purified naive ILC2s treated with IL-33, leukotrienes, and inhibitors for nuclear factor of activated T cells, p38, c-Jun N-terminal kinase, or nuclear factor κ light-chain enhancer of activated B cells. The pathogenesis of IL-17+ ILC2s was determined by transferring wild-type or Il17-/- ILC2s to Rag2-/-Il2rg-/-mice, which further induced lung inflammation. Finally, expression of 106 ILC2 signature genes was compared between ST2+IL-17+ ILC2s and ST2+IL-17- ILC2s. RESULTS: Papain or IL-33 treatment boosted IL-17 production from ST2+ ILC2s (referred to by us as ILC217s) but not ST2- ILC2s. Ahr, but not retinoic acid receptor-related orphan receptor γt, facilitated the production of IL-17 by ILC217s. The hematopoietic compartment of MyD88 signaling is essential for ILC217 induction. IL-33 works in synergy with leukotrienes, which signal through nuclear factor of activated T-cell activation to promote IL-17 in ILC217s. Il17-/- ILC2s were less pathogenic in lung inflammation. ILC217s concomitantly expressed IL-5 and IL-13 but expressed little GM-CSF. CONCLUSION: During lung inflammation, IL-33 and leukotrienes synergistically induce ILC217s. ILC217s are a highly pathogenic and unexpected source for IL-17 in lung inflammation.
Authors: S Molet; Q Hamid; F Davoine; E Nutku; R Taha; N Pagé; R Olivenstein; J Elias; J Chakir Journal: J Allergy Clin Immunol Date: 2001-09 Impact factor: 10.793
Authors: Hye Young Kim; Ya-Jen Chang; Ya-Ting Chuang; Hyun-Hee Lee; David I Kasahara; Thomas Martin; Joyce T Hsu; Paul B Savage; Stephanie A Shore; Gordon J Freeman; Rosemarie H Dekruyff; Dale T Umetsu Journal: J Allergy Clin Immunol Date: 2013-05-11 Impact factor: 10.793
Authors: Ben Roediger; Ryan Kyle; Kwok Ho Yip; Nital Sumaria; Thomas V Guy; Brian S Kim; Andrew J Mitchell; Szun S Tay; Rohit Jain; Elizabeth Forbes-Blom; Xi Chen; Philip L Tong; Holly A Bolton; David Artis; William E Paul; Barbara Fazekas de St Groth; Michele A Grimbaldeston; Graham Le Gros; Wolfgang Weninger Journal: Nat Immunol Date: 2013-04-21 Impact factor: 25.606
Authors: Yuefeng Huang; Liying Guo; Jin Qiu; Xi Chen; Jane Hu-Li; Ulrich Siebenlist; Peter R Williamson; Joseph F Urban; William E Paul Journal: Nat Immunol Date: 2014-12-22 Impact factor: 25.606
Authors: William D Cornwell; Cynthia Kim; Alejandra C Lastra; Chandra Dass; Sudhir Bolla; He Wang; Huaqing Zhao; Frederick V Ramsey; Nathaniel Marchetti; Thomas J Rogers; Gerard J Criner Journal: Biomarkers Date: 2018-11-19 Impact factor: 2.658
Authors: Chhinder P Sodhi; Jenny Nguyen; Yukihiro Yamaguchi; Adam D Werts; Peng Lu; Mitchell R Ladd; William B Fulton; Mark L Kovler; Sanxia Wang; Thomas Prindle; Yong Zhang; Eric D Lazartigues; Michael J Holtzman; John F Alcorn; David J Hackam; Hongpeng Jia Journal: J Immunol Date: 2019-10-23 Impact factor: 5.422